Balancing Expediency and Scientific Rigor in Severe Acute Respiratory Syndrome Coronavirus 2 Vaccine Development

Kevin W Graepel¹, Sonali Kochhar^{2

3}, Ellen W Clayton^{4

5

6}, Kathryn E Edwards⁷

Affiliations

¹ Vanderbilt University School of Medicine, Nashville, Tennessee, USA.
² Global Healthcare Consulting, New Delhi, India.
³ Department of Global Health, Schools of Medicine and Public Health, University of Washington, Seattle, Washington, USA.
⁴ Department of Pediatrics, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
⁵ Center for Biomedical Ethics and Society and Department of Health Policy, Vanderbilt University School of Medicine, Nashville, Tennessee, USA.
⁶ Vanderbilt University Law School, Nashville, Tennessee, USA.
⁷ Division of Pediatric Infectious Diseases, Department of Pediatrics, Vanderbilt University Medical Center, Nashville, Tennessee, USA.

Kevin W Graepel et al. J Infect Dis. 2020.

. 2020 Jun 29;222(2):180-182.

doi: 10.1093/infdis/jiaa234.

Kevin W Graepel¹, Sonali Kochhar^{2

3}, Ellen W Clayton^{4

5

6}, Kathryn E Edwards⁷

¹ Vanderbilt University School of Medicine, Nashville, Tennessee, USA.
² Global Healthcare Consulting, New Delhi, India.
³ Department of Global Health, Schools of Medicine and Public Health, University of Washington, Seattle, Washington, USA.
⁴ Department of Pediatrics, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
⁵ Center for Biomedical Ethics and Society and Department of Health Policy, Vanderbilt University School of Medicine, Nashville, Tennessee, USA.
⁶ Vanderbilt University Law School, Nashville, Tennessee, USA.
⁷ Division of Pediatric Infectious Diseases, Department of Pediatrics, Vanderbilt University Medical Center, Nashville, Tennessee, USA.

No abstract available

Comment in

Immunosenescence and Severe Acute Respiratory Syndrome Coronavirus 2 Vaccine Development.
Nalin D. Nalin D. J Infect Dis. 2020 Nov 13;222(12):2114. doi: 10.1093/infdis/jiaa564. J Infect Dis. 2020. PMID: 32887991 Free PMC article. No abstract available.

1. Le TT, Andreadakis Z, Kumar A, et al. . The COVID-19 vaccine development landscape [manuscript published online ahead of print 9 April 2020]. Nat Rev Drug Discov 2020. doi:10.1038/d41573-020-00073-5. - PubMed
1. World Health Organization. Draft landscape of COVID-19 candidate vaccines—23 April 2020 https://www.who.int/blueprint/priority-diseases/key-action/draft-landsca.... Accessed 24 April 2020.
1. Wu F, Wang A, Liu M, et al. . Neutralizing antibody responses to SARS-CoV-2 in a COVID-19 recovered patient cohort and their implications. medRxiv [Preprint]. 20 April 2020. 10.1101/2020.03.30.20047365. Accessed 16 April 2020. - DOI
1. Bao L, Deng W, Gao H, et al. . Reinfection could not occur in SARS-CoV-2 infected rhesus macaques. bioRxiv [Preprint]. 14 March 2020. 10.1101/2020.03.13.990226. Accessed 16 April 2020. - DOI
1. Modjarrad K, Roberts CC, Mills KT, et al. . Safety and immunogenicity of an anti-Middle East respiratory syndrome coronavirus DNA vaccine: a phase 1, open-label, single-arm, dose-escalation trial. Lancet Infect Dis 2019; 19:1013–22. - PMC - PubMed